308 results
8-K
EX-99.1
INVA
Innoviva Inc
6 Nov 23
Regulation FD Disclosure
8:30am
) in participants who had a positive culture for gonorrhea at baseline. Secondary analyses were microbiological cure at rectal or pharyngeal sites and safety … cure at rectal or pharyngeal sites at TOC (day 6 “ 2); safety Oral dose zoliflodacin (3g) Ceftriaxone IM injection (500mg) + oral azithromycin (1g
8-K
EX-99.1
INVA
Innoviva Inc
1 Nov 23
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:30pm
of ceftriaxone and oral azithromycin, a current global standard of care regimen. In the study, zoliflodacin demonstrated a favorable safety profile
8-K
EX-99.1
x158 w8zl7z03cxi4ju
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99.1
jwa3h0 l3
9 Nov 22
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:17pm
8-K
EX-99.1
l2dn3gtgh78uc
23 Aug 22
Other Events
4:08pm
8-K
EX-10.1
nsdwg
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
EX-2.1
zw5ae06vcmejmcx
11 Jul 22
Information about tender offer
3:46pm
8-K
EX-2.1
voo0z5
11 Jul 22
Innoviva to Acquire La Jolla Pharmaceutical Company
7:38am
425
ot8pi2xnrze9
11 Jul 22
Business combination disclosure
7:38am
SC TO-C
EX-2.1
gaqzyhw 57nx
23 May 22
Information about tender offer
8:53pm
8-K
EX-2.1
l36z5s v88kkp24lmk
23 May 22
Tender and Support Agreement
8:51pm
8-K
EX-99.1
iu6h5ao
7 Apr 22
Regulation FD Disclosure
5:09pm